Amandine Verlande

Amandine Verlande

Auto-generated profile, based on publicly available information

Amandine Verlande

Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Science Advances
Verified
Journal Article
Open access
SCSung Kook Chun
Sung Kook Chun
BFBridget M. Fortin
Bridget M. Fortin
RFRachel C. Fellows
Rachel C. Fellows
AHAmber N Habowski
Amber N Habowski
AVAmandine Verlande
Amandine Verlande
SMSelma Masri
Selma Masri
An alarming rise in young onset colorectal cancer (CRC) has been reported; however, the underlying molecular mechanism remains undefined. Suspected risk factors of young onset CRC include environmental aspects, such as lifestyle and dietary factors, which are known to affect the circadian clock. We find that both genetic disruption and environmental disruption of the circadian clock accelerate Apc- driven CRC pathogenesis in vivo. Using an intestinal organoid model, we demonstrate that clock disruption promotes transformation by driving Apc loss of heterozygosity, which hyperactivates Wnt signaling. This up-regulates c-Myc , a known Wnt target, which drives heightened glycolytic metabolism. Using patient-derived organoids, we show that circadian rhythms are lost in human tumors. Last, we identify that variance between core clock and Wnt pathway genes significantly predicts the survival of patients with CRC. Overall, our findings demonstrate a previously unidentified mechanistic link between clock disruption and CRC, which has important implications for young onset cancer prevention.

25 June 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
AVAmandine Verlande
Amandine Verlande
SCSung Kook Chun
Sung Kook Chun
MGMaggie O. Goodson
Maggie O. Goodson
BFBridget M. Fortin
Bridget M. Fortin
HBHosung Bae
Hosung Bae
SMSelma Masri
Selma Masri
Glucagon signaling governs REV-ERBα stability to modulate hepatic glucose production in a model of lung cancer cachexia.

10 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Veronika PalušováVeronika Palušová
Veronika Palušová
TRTereza Renzová
Tereza Renzová
AVAmandine Verlande
Amandine Verlande
TVTereza Vaclova
Tereza Vaclova
MMMichaela Medková
Michaela Medková
SUStjepan Uldrijan
Stjepan Uldrijan
BRAF inhibitors can delay the progression of metastatic melanoma, but resistance usually emerges, leading to relapse. Drugs simultaneously targeting two or more pathways essential for cancer growth could slow or prevent the development of resistant clones. Here, we identified pyridinyl imidazole compounds SB202190, SB203580, and SB590885 as dual inhibitors of critical proliferative pathways in human melanoma cells bearing the V600E activating mutation of BRAF kinase. We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells. Pyridinyl imidazole compounds directly inhibit BRAF V600E kinase. Moreover, they interfere with the endolysosomal compartment, promoting the accumulation of large acidic vacuole-like vesicles and dynamic changes in mTOR signaling. A transient increase in mTORC1 activity is followed by the enrichment of the Ragulator complex protein p18/LAMTOR1 at contact sites of large vesicles and delocalization of mTOR from the lysosomes. The induced disruption of the endolysosomal pathway not only disrupts mTORC1 signaling, but also renders melanoma cells sensitive to endoplasmic reticulum (ER) stress. Our findings identify new activities of pharmacologically relevant small molecule compounds and provide a biological rationale for the development of anti-melanoma therapeutics based on the pyridinyl imidazole core.

22 December 2017 in EMBO Reports
Verified
Journal Article
Closed access
AVAmandine Verlande
Amandine Verlande
MKMichaela Krafčíková
Michaela Krafčíková
DPDavid Potěšil
David Potěšil
LTLukáš Trantírek
Lukáš Trantírek
ZZZbyněk Zdráhal
Zbyněk Zdráhal
SUStjepan Uldrijan
Stjepan Uldrijan

30 May 2023 in EMBO Reports
Verified
Journal Article
Open access
MDMorgan Dragan
Morgan Dragan
ZCZeyu Chen
Zeyu Chen
YLYumei Li
Yumei Li
JLJohnny Le
Johnny Le
PSPeng Sun
Peng Sun
XDXing Dai
Xing Dai
Skin epidermis constitutes the outer permeability barrier that protects the body from dehydration, heat loss, and myriad external assaults. Mechanisms that maintain barrier integrity in constantly challenged adult skin and how epidermal dysregulation shapes the local immune microenvironment and whole-body metabolism remain poorly understood. Here, we demonstrate that inducible and simultaneous ablation of transcription factor-encoding Ovol1 and Ovol2 in adult epidermis results in barrier dysregulation through impacting epithelial-mesenchymal plasticity and inflammatory gene expression. We find that aberrant skin immune activation then ensues, featuring Langerhans cell mobilization and T cell responses, and leading to elevated levels of secreted inflammatory factors in circulation. Finally, we identify failure to gain body weight and accumulate body fat as long-term consequences of epidermal-specific Ovol1/2 loss and show that these global metabolic changes along with the skin barrier/immune defects are partially rescued by immunosuppressant dexamethasone. Collectively, our study reveals key regulators of adult barrier maintenance and suggests a causal connection between epidermal dysregulation and whole-body metabolism that is in part mediated through aberrant immune activation.